Atlas Trials

Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients

Clinical trial NCT05984615 · COMPLETED

Trial details

NCT number
NCT05984615
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Study type
OBSERVATIONAL
BRAF Positive Metastatic Melanoma
Start date
2022-06-08
Primary completion
2022-08-24
Enrollment
1961

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.